METTL3 and small cell lung carcinoma: However, a new, highly selective, oral METTL3 inhibitor, STM2457, abrogates the resistance of SCLC cells to chemotherapy both in vitro and in vivo, indicating its potential for treating chemotherapy-resistant SCLC patients [104].